"10.1371_journal.pone.0084821","plos one","2014-01-06T00:00:00Z","Jamie L Brugnano; Alyssa Panitch","Weldon School of Biomedical Engineering, Purdue University, West Lafayette, Indiana, United States of America","Conceived and designed the experiments: JLB AP. Performed the experiments: JLB. Analyzed the data: JLB AP. Contributed reagents/materials/analysis tools: AP. Wrote the paper: JLB AP.","Alyssa Panitch is a founder of Moerae Matrix, Inc. and holds greater than 5% interest in the company. Moerae Matrix Inc. holds and exclusive license to the cell-penetrating peptide described in this work. This does not alter the authors’ adherence to all the PLOS ONE policies on sharing data and materials. The following patent has been issued on the composition of the YARA peptide described herein (MK2 inhibitor peptide/HSP27 kinase inhibitor). “Polypeptide inhibitors of HSP27 kinase and uses therefor.” United States Patent 8,536,303. The patent also discloses medical uses of the peptide. The in vitro delivery of the peptide, as describe herein, is not subject to any patents or patent applications.","2014","01","Jamie L Brugnano","JLB",2,TRUE,2,1,2,2,TRUE,TRUE,FALSE,0,NA,FALSE
